Insight, market monitoring and assessing whether a brand plan is fit for purposeThis article is the last in a series of three from Osprey Health Consulting. In this third article Share XInsight, market monitoring and assessing whether a brand plan is fit for purposehttps://pharmaphorum.com/views-analysis-sales-marketing/insight-market-monitoring-and-assessing-whether-a-brand-plan-is-fit-for-purpose/
Frontiers Health 2018 Live Day TwoWhat does digital disruption mean for healthcare? Who are the main players driving innovation? What does this mean Share XFrontiers Health 2018 Live Day Twohttps://pharmaphorum.com/views-analysis-digital/frontiers-health-2018-live-day-two/
Frontiers Health 2018 Live Day OneFrontiers Health is the leading global conference focused on digital disruption and use of technologies within healthcare. The Share XFrontiers Health 2018 Live Day Onehttps://pharmaphorum.com/views-analysis-digital/frontiers-health-2018-live-day-one/
Brand planning in complex and uncertain marketsIn our first article we addressed the modern challenges to strategic planning; the growing complexity and uncertainty that Share XBrand planning in complex and uncertain marketshttps://pharmaphorum.com/views-analysis-sales-marketing/brand-planning-in-complex-and-uncertain-markets/
Balancing expectations: An unmet need in the orphan disease arenaThere are between 6000 and 8000 rare diseases in the world, and one in ten people in Europe Share XBalancing expectations: An unmet need in the orphan disease arenahttps://pharmaphorum.com/views-analysis-market-access/balancing-expectations-rare-disease-arena/
Disease spotlight: Duchenne muscular dystrophy (DMD)Duchenne muscular dystrophy (DMD) is a genetic disorder characterised by progressive muscle degeneration and weakness.Duchenne is a rare Share XDisease spotlight: Duchenne muscular dystrophy (DMD)https://pharmaphorum.com/views-and-analysis/duchenne-muscular-dystrophy/
Disease spotlight: LHONLeber’s hereditary optic neuropathy (LHON) is a rare, progressive, hereditary condition that leads to blindness in young adults.The Share XDisease spotlight: LHONhttps://pharmaphorum.com/views-and-analysis/therapy-area-spotlight/
CAR-Ts dominated the agenda at ASH 2017The American Society for Hematology congress was dominated by CAR-T therapies – their potential new uses, how to Share XCAR-Ts dominated the agenda at ASH 2017https://pharmaphorum.com/views-analysis-oncology/car-ts-dominated-agenda-ash-2017/
11/23/2017The evolution of pharma social media intelligenceIs your company a fully mature user of intelligence from social media, or is it still not tapping Share XThe evolution of pharma social media intelligencehttps://pharmaphorum.com/debates-insight-sales-marketing/evolution-pharma-social-media-intelligence/
